Previous 10 | Next 10 |
2023-09-22 09:54:38 ET Summary Krystal Biotech, Inc. received FDA approval of Vyjuvek, for the treatment of patients with dystrophic epidermolysis bullosa in May of 2023. FDA IND clearance of KB408 for the treatment of patients with antitrypsin deficiency given; Phase 1 study expe...
2023-09-21 13:20:11 ET More on Krystal Biotech Seeking Alpha’s Quant Rating on Krystal Biotech Financial information for Krystal Biotech Krystal Biotech: Pioneering Rare Disease Gene Therapies Berenberg starts Krystal Biotech at buy, cites upcoming dru...
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic med...
2023-09-13 06:31:15 ET More on Krystal Biotech Seeking Alpha’s Quant Rating on Krystal Biotech Historical earnings data for Krystal Biotech Berenberg starts Krystal Biotech at buy, cites upcoming drug launch Krystal Biotech IND application for solid tu...
2023-09-07 18:03:10 ET More on Krystal Biotech Seeking Alpha’s Quant Rating on Krystal Biotech Historical earnings data for Krystal Biotech Financial information for Krystal Biotech Krystal Biotech: Pioneering Rare Disease Gene Therapies Krysta...
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, ann...
2023-09-05 11:40:20 ET More on Krystal Biotech Seeking Alpha’s Quant Rating on Krystal Biotech Historical earnings data for Krystal Biotech Financial information for Krystal Biotech Krystal Biotech: Pioneering Rare Disease Gene Therapies Krysta...
KB408 IND filed on August 15, 2023 PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to tr...
2023-08-21 07:31:33 ET More on Krystal Biotech Krystal Biotech: Pioneering Rare Disease Gene Therapies Seeking Alpha’s Quant Rating on Krystal Biotech Earnings data for Krystal Biotech For further details see: Krystal Biotech announces sale of prio...
PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs, announced t...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...